Browsing by Author "b5d9690a-e30a-4363-8dc9-50d46c5062a2"

Now showing items 1-3 of 3

    • GDF-11 prevents cardiomyocyte hypertrophy by maintaining the sarcoplasmic reticulum-mitochondria communication 
      Garrido-Moreno, Valeria; Díaz Vegas, Alexis; López Crisosto, Camila; Troncoso, Mayarling Francisca; Navarro Márquez, Mario F.; García Nannig, Lorena; Estrada, Manuel; Cifuentes, Mariana; Lavandero González, Sergio (Academic Press, 2019)
      Growth differentiation factor 11 (GDF11) is a novel factor with controversial effects on cardiac hypertrophy both in vivo and in vitro. Although recent evidence has corroborated that GDF11 prevents the development of cardiac ...
    • Herpud1 negatively regulates pathological cardiac hypertrophy by inducing IP3 receptor degradation 
      Torrealba, Natalia; Navarro Márquez, Mario F.; Vega Garrido, Valeria; Pedrozo Cibils, Zully; Romero, Diego; Eura, Yuka; Villalobos, Elisa; Carlos Roa, Juan; Chiong Lay, Mario; Kokame, Koichi; Lavandero González, Sergio (Nature Publishing Group, 2017)
      Cardiac hypertrophy is an adaptive response triggered by pathological stimuli. Regulation of the synthesis and the degradation of the Ca2+ channel inositol 1,4,5-trisphosphate receptor (IP3R) affects progression to cardiac ...
    • Mifepristone enhances insulin stimulated Akt phosphorylation and glucose uptake in skeletal muscle cells 
      Bernal Sore, Izela; Navarro Márquez, Mario F.; Osorio Fuentealba, César; Díaz Castro, Francisco; Campo, Andrea del; Donoso Barraza, Camila; Porras Espinoza, Omar; Lavandero González, Sergio; Troncoso Cotal, Rodrigo (Elsevier, 2018)
      Mifepristone is the only FDA-approved drug for glycaemia control in patients with Cushing's syndrome and type 2 diabetes. Mifepristone also has beneficial effects in animal models of diabetes and patients with antipsychotic ...